The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lodosin     (2S)-3-(3,4-dihydroxyphenyl)- 2-hydrazinyl...

Synonyms: Lodosyn, carbidopa, Atamet, Carbidopum, MK-485, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MK 486


Psychiatry related information on MK 486


High impact information on MK 486


Chemical compound and disease context of MK 486


Biological context of MK 486

  • Additional specimens were incubated with 3H-5-HTP and carbidopa, an inhibitor of DOPA-decarboxylase, used to block the decarboxylation of 3H-5-HTP to 3H-5-HT, or with 3H-5-HT, used to determine where exogenous 3H-5-HT localizes in the pyloric mucosa [21].
  • LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo [22].
  • Elevation of brain catecholamine levels by systemic administration of L-dopa in dogs pretreated with the dopa decarboxylase inhibitor carbidopa inhibits the secretion of vasopressin and adrenocorticotropic hormone (ACTH) and decreases arterial blood pressure [23].
  • Carbidopa and MFMD were lethal (IC50 = 29 +/- 2 microM and 56 +/- 6 microM, respectively); NSD-1015 had no effect on proliferation [24].
  • Visual acuity significantly improved by one line, from an overall average of 20/121 to 20/96, in the amblyopic eyes of both groups that received levodopa/carbidopa [25].

Anatomical context of MK 486


Associations of MK 486 with other chemical compounds


Gene context of MK 486


Analytical, diagnostic and therapeutic context of MK 486


  1. Treatment of parkinson's disease with bromocriptine. Lieberman, A., Kupersmith, M., Estey, E., Goldstein, M. N. Engl. J. Med. (1976) [Pubmed]
  2. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. Van Woert, M.H., Rosenbaum, D., Howieson, J., Bowers, M.B. N. Engl. J. Med. (1977) [Pubmed]
  3. Treatment of Parkinson's disease with lergotrile mesylate. Lieberman, A., Estey, E., Kupersmith, M., Gopinathan, G., Goldstein, M. JAMA (1977) [Pubmed]
  4. Manipulation of brain serotonin in the treatment of myoclonus. Chadwick, D., Jenner, P., Harris, R., Reynolds, E.H., Marsden, C.D. Lancet (1975) [Pubmed]
  5. Drugs five years later. Bromocriptine. Vance, M.L., Evans, W.S., Thorner, M.O. Ann. Intern. Med. (1984) [Pubmed]
  6. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. Timmers, H.J., Hadi, M., Carrasquillo, J.A., Chen, C.C., Martiniova, L., Whatley, M., Ling, A., Eisenhofer, G., Adams, K.T., Pacak, K. J. Nucl. Med. (2007) [Pubmed]
  7. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Earley, C.J., Allen, R.P. Sleep. (1996) [Pubmed]
  8. A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis. Oren, D.A., Moul, D.E., Schwartz, P.J., Wehr, T.A., Rosenthal, N.E. Journal of clinical psychopharmacology. (1994) [Pubmed]
  9. Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception. Possible implications in migraine prophylaxis. Genazzani, A.R., Sandrini, G., Facchinetti, F., Rizzo, V., Alfonsi, E., Sances, G., Calvani, M., Nappi, G. Cephalalgia : an international journal of headache. (1986) [Pubmed]
  10. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Smith, L.A., Tel, B.C., Jackson, M.J., Hansard, M.J., Braceras, R., Bonhomme, C., Chezaubernard, C., Del Signore, S., Rose, S., Jenner, P. Mov. Disord. (2002) [Pubmed]
  11. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease. Golbe, L.I., Duvoisin, R.C. J. Neural Transm. Suppl. (1987) [Pubmed]
  12. Suppression of noradrenaline synthesis in sympathetic nerves by carbidopa, an inhibitor of peripheral dopa decarboxylase. Wurtman, R.J., Watkins, C.J. Nature (1977) [Pubmed]
  13. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Boomsma, F., Meerwaldt, J.D., Man in 't Veld, A.J., Hovestadt, A., Schalekamp, M.A. Ann. Neurol. (1989) [Pubmed]
  14. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt, J.G., Woodward, W.R., Anderson, J.L. Ann. Neurol. (1985) [Pubmed]
  15. Dopaminergic deficiency and delayed visual evoked potentials in humans. Bodis-Wollner, I., Yahr, M.D., Mylin, L., Thornton, J. Ann. Neurol. (1982) [Pubmed]
  16. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Lieberman, A., Imke, S., Muenter, M., Wheeler, K., Ahlskog, J.E., Matsumoto, J.Y., Maraganore, D.M., Wright, K.F., Schoenfelder, J. Neurology (1993) [Pubmed]
  17. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman, A.N., Goldstein, M., Gopinathan, G., Neophytides, A., Hiesiger, E., Walker, R., Nelson, J. Neurology (1984) [Pubmed]
  18. Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. Kumar, R., Lang, A.E. Neurology (1997) [Pubmed]
  19. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Van Woert, M.H., Sethy, V.H. Neurology (1975) [Pubmed]
  20. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa. Extein, I., Van Woert, M., Roth, R.H., Bowers, M.B. Biol. Psychiatry (1976) [Pubmed]
  21. An electron microscopic radioautographic identification of the APUD endocrine cells in the rat gastric pyloric glands. Rubin, W., Schwartz, B. Gastroenterology (1981) [Pubmed]
  22. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Kompoliti, K., Adler, C.H., Raman, R., Pincus, J.H., Leibowitz, M.T., Ferry, J.J., Blasucci, L., Caviness, J.N., Leurgans, S., Chase, W.M., Yones, L.C., Tan, E., Carvey, P., Goetz, C.G. Neurology (2002) [Pubmed]
  23. Role of dopamine in the inhibition of vasopressin secretion by L-dopa in carbidopa-treated dogs. Reid, I.A., Chou, L., Chang, D., Keil, L.C. Hypertension (1986) [Pubmed]
  24. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Gilbert, J.A., Frederick, L.M., Ames, M.M. Clin. Cancer Res. (2000) [Pubmed]
  25. Levodopa/carbidopa for childhood amblyopia. Leguire, L.E., Rogers, G.L., Bremer, D.L., Walson, P.D., McGregor, M.L. Invest. Ophthalmol. Vis. Sci. (1993) [Pubmed]
  26. Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man. Caldara, R., Barbieri, C., Piepoli, V., Borzio, M., Masci, E. Gut (1985) [Pubmed]
  27. Endogenous dopamine regulates phosphate reabsorption but not NaK-ATPase in spontaneously hypertensive rat kidneys. Debska-Slizien, A., Ho, P., Drangova, R., Baines, A.D. J. Am. Soc. Nephrol. (1994) [Pubmed]
  28. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Carlson, H.E. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  29. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. Cumming, P., Ase, A., Laliberté, C., Kuwabara, H., Gjedde, A. J. Cereb. Blood Flow Metab. (1997) [Pubmed]
  30. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Spencer, S.E., Wooten, G.F. Neurology (1984) [Pubmed]
  31. Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. Bigelow, L.B., Walls, P., Gillin, J.C., Wyatt, R.J. Biol. Psychiatry (1979) [Pubmed]
  32. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Yeh, K.C., August, T.F., Bush, D.F., Lasseter, K.C., Musson, D.G., Schwartz, S., Smith, M.E., Titus, D.C. Neurology (1989) [Pubmed]
  33. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Ahlskog, J.E., Uitti, R.J., Low, P.A., Tyce, G.M., O'Brien, J.F., Nickander, K.K. Neurology (1996) [Pubmed]
  34. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. Keränen, T., Gordin, A., Koulu, M., Scheinin, M., Antila, S., Sundberg, S., Wikberg, T. Journal of neural transmission (Vienna, Austria : 1996) (1996) [Pubmed]
  35. L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase. Schultz, E. Biomed. Chromatogr. (1990) [Pubmed]
  36. Lithium decreases 5-HT1A and 5-HT2 receptor and alpha 2-adrenoceptor mediated function in mice. Goodwin, G.M., DeSouza, R.J., Wood, A.J., Green, A.R. Psychopharmacology (Berl.) (1986) [Pubmed]
  37. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. Lyras, L., Zeng, B.Y., McKenzie, G., Pearce, R.K., Halliwell, B., Jenner, P. Journal of neural transmission (Vienna, Austria : 1996) (2002) [Pubmed]
  38. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys. Alexander, G.M., Schwartzman, R.J., Grothusen, J.R., Gordon, S.W. Neurology (1994) [Pubmed]
  39. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. Van Horn, G., Schiess, M.C. Neurology (2000) [Pubmed]
  40. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Hutton, J.T., Koller, W.C., Ahlskog, J.E., Pahwa, R., Hurtig, H.I., Stern, M.B., Hiner, B.C., Lieberman, A., Pfeiffer, R.F., Rodnitzky, R.L., Waters, C.H., Muenter, M.D., Adler, C.H., Morris, J.L. Neurology (1996) [Pubmed]
  41. Familial parkinsonism, apathy, weight loss, and central hypoventilation: successful long-term management. Roy, E.P., Riggs, J.E., Martin, J.D., Ringel, R.A., Gutmann, L. Neurology (1988) [Pubmed]
WikiGenes - Universities